C. O’Brien

发表

The hospitalized patient with abnormal liver function tests.

C. O’Brien, 2009, Clinics in liver disease.

A Randomized, Controlled Trial of Interferon Alfa-2b Alone and after Prednisone Withdrawal for the Treatment of Chronic Hepatitis B

E. Schiff, R. Sampliner, J. Albrecht, 1990 .

Tenofovir Therapy for Lamivudine Resistance Following Liver Transplantation

E. Schiff, N. Shire, J. Madariaga, 2004, The Annals of pharmacotherapy.

Viral Hepatitis B, C and D in ALF and ALF/CLD

Alexander M. Sy, C. O’Brien, 2020 .

Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B.

Stefan Zeuzem, M. Buti, Y. Liaw, 2009, Journal of hepatology.

Outcomes in liver transplant recipients with hepatitis B virus: Resistance and recurrence patterns from a large transplant center over the last decade

E. Schiff, N. Shire, J. Madariaga, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Management of Patients with Chronic Hepatitis B Before and After Liver Transplantation: An Update

Paul L. Martin, Andres F Carrion, C. O’Brien, 2012, Current Hepatitis Reports.

Antiviral Chemotherapy for Viral Hepatitis

D. Moonka, C. O’Brien, 1999 .

Factors that identify survival after liver retransplantation for allograft failure caused by recurrent hepatitis C infection

N. Shire, S. Nishida, J. Madariaga, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Treatment of Established Recurrent Hepatitis C in Liver-Transplant Recipients with Pegylated Interferon-alfa-2b and Ribavirin Therapy

E. Schiff, A. Khaled, P. Bejarano, 2004, Transplantation.

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels.

K. Reddy, S. Zeuzem, M. Shiffman, 2004, Gastroenterology.

[6] VALOPICITABINE (NM283), ALONE OR WITH PEG-INTERFERON, COMPARED TO PEG INTERFERON/RIBAVIRIN (PEGIFN/RBV) RETREATMENT IN PATIENTS WITH HCV-1 INFECTION AND PRIOR NON-RESPONSE TO PEGIFN/RBV: ONE-YEAR RESULTS

N. Afdhal, M. Sulkowski, I. Jacobson, 2007 .

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.

Sanjeev Arora, B. Murphy, R. Gish, 2007, Journal of hepatology.

Prediction of sustained virological response in liver transplant recipients with recurrent hepatitis C virus following combination pegylated interferon alfa‐2b and ribavirin therapy using tissue hepatitis C virus reverse transcriptase polymerase chain reaction testing

E. Schiff, A. Khaled, P. Bejarano, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Chemotherapy-induced hepatotoxicity.

C. O'brien, N. Agresti, Ameet V. Thatishetty, 2013, Clinics in liver disease.

Long-term management of alcoholic liver disease.

G. Woo, C. O’Brien, 2012, Clinics in liver disease.

Hepatotoxicity Secondary to Chemotherapy

A. Grigorian, C. O’Brien, 2014, Journal of clinical and translational hepatology.

cDNA Sequencing of the 5′ Noncoding Region (5′ NCR) to Determine Hepatitis C Genotypes in Patients with Chronic Hepatitis C

K. Gutekunst, B. S. Henzel, D. Moonka, 1997, Digestive Diseases and Sciences.

Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.

P. Thuluvath, V. Luketic, N. Pyrsopoulos, 2016, Annals of hepatology.

Drug-induced vanishing bile duct syndrome: response to ursodiol.

K. Reddy, S. Saul, D. S. Shields, 1996, The American journal of gastroenterology.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon α‐2a (40 kDa) plus ribavirin: Impact on health‐related quality of life

Sanjeev Arora, Jesse Green, N. Wintfeld, 2006, Journal of gastroenterology and hepatology.

Preliminary observation with dronabinol in patients with intractable pruritus secondary to cholestatic liver disease

E. Schiff, K. Reddy, N. Bergasa, 2002, American Journal of Gastroenterology.

Safety, efficacy and tolerability of half-dose sofosbuvir plus simeprevir in treatment of Hepatitis C in patients with end stage renal disease.

E. Schiff, D. Roth, C. Levy, 2015, Journal of hepatology.

A Retrospective Review of Liver Transplant Patients Treated with Sirolimus from a Single Center: An Analysis of Sirolimus-Related Complications

A. Tzakis, P. Ruiz, C. O'brien, 2004, Transplantation.

A pilot trial of recombinant interleukin-12 in patients with chronic hepatitis C who previously failed treatment with interferon-α

C. O'brien, B. S. Henzel, D. Moonka, 2001, American Journal of Gastroenterology.

When is it safe to perform abdominal transplantation in patients with prior SARS‐CoV‐2 infection: A case series

J. Figueiró, G. Ciancio, G. Burke, 2021, Clinical transplantation.

Transjugular intrahepatic portosystemic shunting: decreased survival for patients with high APACHE II scores.

Z. Haskal, C. Cope, R. Rubin, 1995, The American journal of gastroenterology.

Hispanics with primary biliary cirrhosis are more likely to have features of autoimmune hepatitis and reduced response to ursodeoxycholic acid than non-Hispanics.

E. Schiff, C. Levy, Paul L. Martin, 2014, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

Ursodeoxycholic acid for the treatment of primary sclerosing cholangitis: A 30‐month pilot study

J. Senior, A. Batta, G. Salen, 1991, Hepatology.

Consumption of dietary supplements in a liver transplant population

S. Nishida, A. Tzakis, C. O'brien, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Reliability of histopathologic assessment for the differentiation of recurrent hepatitis C from acute rejection after liver transplantation

E. Schiff, K. Arheart, M. Berho, 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Effect of long-term treatment with ursodiol on clinical and biochemical features and biliary bile acid metabolism in patients with primary biliary cirrhosis.

J. Senior, G. Tint, A. Batta, 1993, The American journal of gastroenterology.

Sofosbuvir and simeprevir for treatment of hepatitis C virus infection in liver transplant recipients

Paul L. Martin, Andres F Carrion, C. O'brien, 2015, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

Efficacy and safety of simeprevir and sofosbuvir with and without ribavirin in subjects with recurrent genotype 1 hepatitis C postorthotopic liver transplant: the randomized GALAXY study

R. Fontana, K. Brown, Robert S. Brown, 2017, Transplant international : official journal of the European Society for Organ Transplantation.

Sirolimus-Associated Hepatotoxicity in Liver Transplantation

S. Nishida, D. Levi, J. Madariaga, 2004, The Annals of pharmacotherapy.

Efficacy and Safety of Simeprevir and Sofosbuvir with and without Ribavirin for 12 Weeks in Subjects with Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant: The Galaxy Study

R. Fontana, K. Reddy, Robert S. Brown, 2016 .

A multicenter study of recombinant human interleukin 12 for the treatment of chronic hepatitis C virus infection in patients nonresponsive to previous therapy

R. Carithers, J. McHutchison, M. Tong, 2003, Hepatology.

Simultaneous Liver Kidney Transplant in Elderly Patients With Chronic Kidney Disease: Is There an Appropriate Upper Age Cutoff?

D. Goldberg, R. Vianna, Paul L. Martin, 2020, Transplantation.

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life.

Sanjeev Arora, Jesse Green, N. Wintfeld, 2006, Journal of gastroenterology and hepatology.